ASTELLAS PHARMA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.46 USD | +1.26% |
|
+4.39% | -12.10% |
Chart calendar Astellas Pharma Inc.
2d2c5ab4ba69e0.TcBPD9ispjcW6yQXx3kj5C-TcwvfnU4MpbBcdr8CDWQ.DownVYj2i3FyjF5BsBsWqmykFWrs9XZLwtI_Gd1ANR4euRt17-DBDnmYHA~fff26370dffcbe4afcb0cf97eb96049b
Upcoming events on Astellas Pharma Inc.
Past events on Astellas Pharma Inc.
| 2024-06-19 09:00 pm | Annual General Meeting |
| 2024-06-03 02:30 pm | American Society of Clinical Oncology Meeting - Abstract Number : 8585 |
| 2024-06-03 09:00 am | American Society of Clinical Oncology Meeting - Abstract Number : 4502 |
| 2024-06-03 09:00 am | American Society of Clinical Oncology Meeting - Abstract Number : 4503 |
| 2024-06-02 10:00 am | American Society of Clinical Oncology Meeting - Abstract Number : 5087 |
| 2024-06-02 10:00 am | American Society of Clinical Oncology Meeting - Abstract Number : 5084 |
| 2024-06-02 10:00 am | American Society of Clinical Oncology Meeting - Abstract Number : TPS6116 |
| 2024-06-02 10:00 am | American Society of Clinical Oncology Meeting - Abstract Number : 4564 |
| 2024-06-02 10:00 am | American Society of Clinical Oncology Meeting - Abstract Number : 4563 |
| 2024-06-02 10:00 am | American Society of Clinical Oncology Meeting - Abstract Number : 4562 |
| 2024-06-01 04:00 pm | American Society of Clinical Oncology Meeting - Abstract Number : 5005 |
| 2024-06-01 04:00 pm | American Society of Clinical Oncology Meeting - Abstract Number : 1005 |
| 2024-06-01 02:30 pm | American Society of Clinical Oncology Meeting - Abstract Number : 4036 |
| 2024-06-01 02:30 pm | American Society of Clinical Oncology Meeting - Abstract Number : 4046 |
| 2024-05-30 | American Society of Clinical Oncology Meeting - Abstract Number : e23287 |
| 2024-05-30 | American Society of Clinical Oncology Meeting - Abstract Number : e16547 |
| 2024-05-30 | American Society of Clinical Oncology Meeting - Abstract Number : e17071 |
| 2024-04-25 04:00 am | Q4 2023 Earnings Call |
| 2024-04-25 02:00 am | Q4 2023 Earnings Release |
| 2024-04-08 | Cell & Gene Meeting on the Med Conference |
Past dividends on Astellas Pharma Inc.
| 2024-03-27 | Final Payment 35 JPY |
| 2023-09-27 | Interim Payment 35 JPY |
| 2023-03-29 | Final Payment 30 JPY |
| 2022-09-28 | Interim Payment 30 JPY |
| 2022-03-29 | Final Payment 25 JPY |
| 2021-09-28 | Interim Payment 25 JPY |
| 2021-03-29 | Final Payment 21 JPY |
| 2020-09-28 | Interim Payment 21 JPY |
| 2020-03-29 | Final Payment 20 JPY |
| 2019-09-26 | Interim Payment 20 JPY |
Annual results
| Fiscal Period | March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
|
Net sales Million JPY | Released Forecast Spread | 1 300 843 1 274 827 2.04% | 1 249 528 1 258 841 -0.74% | 1 296 163 1 320 041 -1.81% | 1 518 619 1 508 697 0.66% | 1 603 672 1 571 972 2.02% | 1 684 942 |
|
EBITDA Million JPY | Released Forecast Spread | 310 387 316 993 -2.08% | 208 703 300 597 -30.57% | 235 370 316 919 -25.73% | 238 767 321 316 -25.69% | 183 358 264 920 -30.79% | 295 336 |
|
EBIT Million JPY | Released Forecast Spread | 243 991 257 148 -5.12% | 136 051 221 342 -38.53% | 155 686 219 051 -28.93% | 133 029 183 181 -27.38% | 25 518 89 542 -71.5% | 112 065 |
|
Earnings before Tax (EBT) Million JPY | Released Forecast Spread | 245 350 262 926 -6.68% | 145 324 219 749 -33.87% | 156 886 214 703 -26.93% | 132 361 187 029 -29.23% | 24 969 24 853 0.47% | 83 548 |
|
Net income Million JPY | Released Forecast Spread | 195 411 203 519 -3.98% | 120 589 176 431 -31.65% | 124 086 177 294 -30.01% | 98 714 144 398 -31.64% | 17 045 13 409 27.12% | 61 529 |
|
EPS JPY | Released Forecast Spread | 104 113 -7.83% | 64,9 96,5 -32.74% | 67,1 94,2 -28.76% | 54,2 80,3 -32.42% | 9,51 13,2 -28.05% | 34,3 |
| Announcement Date | 14/05/20 | 27/04/21 | 27/04/22 | 27/04/23 | 25/04/24 | - |
Quarterly results
| Fiscal Period | March | 2021 S1 | 2022 S1 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 S1 | 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 S1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million JPY | Released Forecast Spread | 615 480 631 150 -2.48% | 651 666 653 900 -0.34% | 303 870 324 327 -6.31% | 381 791 345 350 10.55% | 380 394 360 355 5.56% | 762 185 748 000 1.9% | 402 180 395 900 1.59% | 354 254 361 045 -1.88% | 374 990 357 906 4.77% | 392 148 355 602 10.28% | 767 138 714 088 7.43% | 421 932 385 383 9.48% | 414 602 381 093 8.79% | 408 971 | 423 400 | 834 303 | 437 313 | 408 999 | 423 823 | 855 237 |
|
EBITDA Million JPY | Released Forecast Spread | 70 087 123 700 -43.34% | 42,0 59 200 -99.93% | 79 800 | 64 400 | 87 500 | 61 700 | ||||||||||||||
|
EBIT Million JPY | Released Forecast Spread | 86 872 139 408 -37.68% | 90 169 138 200 -34.75% | -13 685 41 432 -133.03% | 33 147 47 625 -30.4% | 86 744 75 977 14.17% | 119 891 117 500 2.03% | 61 388 83 350 -26.35% | -48 250 26 250 -283.81% | 45 794 67 478 -32.14% | 5 222 53 977 -90.33% | 51 016 94 059 -45.76% | 23 103 47 250 -51.1% | -48 601 18 027 -369.6% | 38 204 | 44 824 | 82 698 | 57 535 | -8 571 | 29 567 | 65 110 |
|
Earnings before Tax (EBT) Million JPY | Released Forecast Spread | 89 091 139 808 -36.28% | 89 085 143 200 -37.79% | -10 516 41 300 -125.46% | 31 679 48 800 -35.08% | 88 801 95 700 -7.21% | 120 480 115 500 4.31% | 59 758 78 000 -23.39% | -47 877 27 200 -276.02% | 46 850 66 704 -29.76% | 5 328 52 133 -89.78% | 52 178 93 959 -44.47% | 21 452 54 767 -60.83% | -48 661 -57 900 15.96% | 23 044 | 31 873 | 45 598 | 39 791 | -28 018 | 27 817 | 61 610 |
|
Net income Million JPY | Released Forecast Spread | 72 838 110 808 -34.27% | 71 609 113 700 -37.02% | -8 409 32 500 -125.87% | 24 812 35 300 -29.71% | 71 622 74 600 -3.99% | 96 434 90 000 7.15% | 48 405 60 800 -20.39% | -46 125 14 950 -408.53% | 33 129 52 178 -36.51% | -1 459 42 300 -103.45% | 31 670 71 261 -55.56% | 18 653 40 467 -53.91% | -33 278 -44 000 24.37% | 24 519 | 28 357 | 35 163 | 37 430 | -6 658 | 20 585 | 45 592 |
|
EPS JPY | Released Forecast Spread | 39,2 54,5 -28.06% | 38,7 61,4 -37.05% | -4,43 15,9 -127.89% | 13,6 18,6 -27.03% | 39,3 33,6 16.89% | 52,9 46,6 13.45% | 26,6 39,2 -32.31% | -25,2 -20,2 -24.61% | 18,5 29,8 -38.06% | -0,80 23,9 -103.35% | 17,7 41,1 -56.98% | 10,4 15,2 -31.36% | -18,6 -8,52 -117.76% | 9,73 | 14,6 | 17,4 | 20,8 | -23,0 | 11,5 | 25,4 |
| Announcement Date | 30/10/20 | 29/10/21 | 27/04/22 | 01/08/22 | 31/10/22 | 31/10/22 | 06/02/23 | 27/04/23 | 01/08/23 | 01/11/23 | 01/11/23 | 05/02/24 | 25/04/24 | - | - | - | - | - | - | - |
| 2024-07-15 | CAMURUS AB: Q2 2024 Earnings Release |
| 2024-07-16 | GLAND PHARMA LIMITED: Q1 2025 Earnings Release (Projected) |
| 2024-07-17 06:45 am | JOHNSON & JOHNSON: Q2 2024 Earnings Release |
| 2024-07-17 | JUBILANT PHARMOVA LIMITED: Q1 2025 Earnings Release (Projected) |
| 2024-07-18 01:00 am | NOVARTIS AG: Q2 2024 Earnings Release |
| 2024-07-18 | TEYI PHARMACEUTICAL GROUP CO.,LTD: Q2 2024 Earnings Release |
| 2024-07-21 | GLAXOSMITHKLINE PHARMACEUTICALS LIMITED: Q1 2025 Earnings Release (Projected) |
| 2024-07-21 | ALMIRALL, S.A.: Q2 2024 Earnings Release |
| 2024-07-22 | TORRENT PHARMACEUTICALS LIMITED: Q1 2025 Earnings Release (Projected) |
| 2024-07-23 | INNOVIVA, INC.: Q2 2024 Earnings Release (Projected) |
Past sector events for Astellas Pharma Inc.
| 2024-07-10 | HISAMITSU PHARMACEUTICAL CO., INC.: Q1 2025 Earnings Release |
| 2024-07-09 | LOTUS PHARMACEUTICAL CO., LTD.: June 2024 Sales and Revenue Release |
| 2024-07-09 07:35 am | SCINOPHARM TAIWAN, LTD.: June 2024 Sales and Revenue Release |
| 2024-07-03 | HISAMITSU PHARMACEUTICAL CO., INC.: Q1 2024 Earnings Release (Projected) |
| 2024-07-02 05:05 am | ONENESS BIOTECH CO., LTD.: June 2024 Sales and Revenue Release |
| 2024-06-21 11:28 am | DEVA HOLDING: Q1 2024 Earnings Release |
| 2024-06-13 05:21 pm | EIS ECZACIBASI ILAÇ, SINAI VE FINANSAL YATIRIMLAR SANAYI VE TICARET: Q1 2024 Earnings Release |
| 2024-06-11 01:30 am | BORA PHARMACEUTICALS CO., LTD.: June 2024 Sales and Revenue Release |
| 2024-06-07 06:33 am | SCINOPHARM TAIWAN, LTD.: May 2024 Sales and Revenue Release |
| 2024-06-07 05:17 am | LOTUS PHARMACEUTICAL CO., LTD.: May 2024 Sales and Revenue Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- 4503 Stock
- ALPMY Stock
- Calendar Astellas Pharma Inc.
